UPDATE 1-NovaBay skin infection drug shows efficacy in mid stage

* Drug cleared impetigo infections in a mid-stage trial

* Cleared infections caused by a drug-resistant bacteria

July 21 (BestGrowthStock) – NovaBay Pharmaceuticals Inc (NBY.A: )
said its lead product, an experimental treatment for a highly
contagious skin infection, was safe and efficacious in a
mid-stage trial.

The study showed the drug, called NVC-422, cleared impetigo
infections, including those caused by a drug-resistant strain
of bacteria called methicillin-resistant Staphylococcus aureus
(MRSA), the company said.

Three doses of the drug, tested in 129 patients, showed
clinical response rates of 85 percent, 87 percent and 92
percent respectively for the low, medium and high doses,
respectively.

Patients on the trial were treated with NVC-422 gel three
times a day for seven days.

Based on the results of the trial, NovaBay plans to present
its development plans for the drug for the treatment of
impetigo to the U.S. Food and Drug Administration.

Impetigo affect about 1 million people, primarily infants
and children, in the United States annually, NovaBay said in a
statement.

Shares of the company closed at $1.95 Tuesday on the
American Stock Exchange.

Stock Market

(Reporting by Esha Dey in Bangalore; Editing by Jarshad
Kakkrakandy)

UPDATE 1-NovaBay skin infection drug shows efficacy in mid stage